Business Description
ISIN : US6323071042
Total Employee Number:
6,140Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.58 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -1.3 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 33.2 | |||||
Beneish M-Score | 0.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.5 | |||||
3-Year EBITDA Growth Rate | 32.7 | |||||
3-Year EPS without NRI Growth Rate | 35.1 | |||||
3-Year Book Growth Rate | 24.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 21.61 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44 | |||||
9-Day RSI | 53.89 | |||||
14-Day RSI | 58.52 | |||||
3-1 Month Momentum % | 50.89 | |||||
6-1 Month Momentum % | 62.57 | |||||
12-1 Month Momentum % | 92.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3 | |||||
Quick Ratio | 2.85 | |||||
Cash Ratio | 1.97 | |||||
Days Inventory | 26.25 | |||||
Days Sales Outstanding | 46.7 | |||||
Days Payable | 19.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | 0.09 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.23 | |||||
Operating Margin % | -10.7 | |||||
Net Margin % | -7.11 | |||||
EBITDA Margin % | -6.76 | |||||
FCF Margin % | 1.89 | |||||
OCF Margin % | 8.43 | |||||
ROE % | -12.32 | |||||
ROA % | -8.55 | |||||
ROIC % | -23.18 | |||||
3-Year ROIIC % | 38.66 | |||||
ROC (Joel Greenblatt) % | -55.17 | |||||
ROCE % | -14.03 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 16.79 | |||||
PB Ratio | 25.56 | |||||
Price-to-Tangible-Book | 35.27 | |||||
Price-to-Free-Cash-Flow | 876.05 | |||||
Price-to-Operating-Cash-Flow | 198.49 | |||||
EV-to-EBIT | -184.3 | |||||
EV-to-Forward-EBIT | -1086.96 | |||||
EV-to-EBITDA | -250.54 | |||||
EV-to-Forward-EBITDA | 3491.53 | |||||
EV-to-Revenue | 16.94 | |||||
EV-to-Forward-Revenue | 12.63 | |||||
EV-to-FCF | 895.95 | |||||
Price-to-GF-Value | 1.48 | |||||
Price-to-Median-PS-Value | 2.25 | |||||
| Price-to-Net-Current-Asset-Value | 56.57 | |||||
| Price-to-Net-Cash | 182.1 | |||||
Earnings Yield (Greenblatt) % | -0.54 | |||||
FCF Yield % | 0.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NTRA
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Natera Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,707.075 | ||
| EPS (TTM) ($) | -1.35 | ||
| Beta | 2.3902 | ||
| 3-Year Sharpe Ratio | 1.26 | ||
| 3-Year Sortino Ratio | 2.78 | ||
| Volatility % | 41.85 | ||
| 14-Day RSI | 58.52 | ||
| 14-Day ATR ($) | 11.183027 | ||
| 20-Day SMA ($) | 323.64575 | ||
| 12-1 Month Momentum % | 92.42 | ||
| 52-Week Range ($) | 157.425 - 343.18 | ||
| Shares Outstanding (Mil) | 144.14 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Natera Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Natera Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 171 days | ||
| Annual report for 2026 | 2027-02-26 | In 170 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 170 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 59 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 58 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 274.62 (-0.21%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 274.62 (-0.21%) | ||
| General meeting for 2026 | 2026-06-11 11:30 | 216.50 (-2.33%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 215.09 (+3.14%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 215.09 (+3.14%) |
Natera Inc Frequently Asked Questions
Guru Commentaries on NAS:NTRA
We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We are particularly excited about the promise of Natera's Signatera minimal residual disease (MRD) tests, which account for half of the company's revenues today and are the company's key growth driver. Signatera tests for any evidence of cancer cell DNA in a patient's blood and can be used to stratify patients, monitor treatment responses, and detect early cancer recurrence. Natera continues to invest in clinical studies to prove Signatera’s clinical value in additional treatment settings.
We upgraded our health care exposure with the purchase of Natera, a molecular diagnostics company that specializes in cell-free DNA testing across oncology, women’s health and organ health. We believe Natera has a long runway for growth as adoption of minimal residual disease (MRD) testing, a nascent post-cancer treatment area, increases. The company has multiple opportunities to broaden its MRD portfolio and extend its reach globally. While Natera is investing heavily in oncology today, its core women’s health business is currently profitable, allowing the company to be self-funded.
Natera, Inc. is an innovative market leader in the growing and under-penetrated liquid biopsy market, with the potential for meaningful profitability at scale. We were able to invest in the stock after it had fallen from its highs.
Press Release
Articles on Natera Inc
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
